Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder.^[1] It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist.^[1][2][3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect.^[4][5] Although Lybalvi still produces weight gain at a similar rate to other antipsychotics, such as quetiapine and risperidone, its metabolic profile is significantly lower than olanzapine alone. The formulation was approved for medical use in the United States in May 2021.^[1][6]

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

• v
• t
• e